Compare SFST & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | IVVD |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.7M | 437.1M |
| IPO Year | 2012 | 2021 |
| Metric | SFST | IVVD |
|---|---|---|
| Price | $58.69 | $1.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $64.00 | $8.75 |
| AVG Volume (30 Days) | 97.5K | ★ 3.6M |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | 79.02 |
| EPS | ★ 3.72 | N/A |
| Revenue | $6,282,000.00 | ★ $53,426,000.00 |
| Revenue This Year | $10.47 | $147.67 |
| Revenue Next Year | $12.19 | $22.76 |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | 12.99 | ★ 110.47 |
| 52 Week Low | $30.68 | $0.46 |
| 52 Week High | $62.00 | $3.07 |
| Indicator | SFST | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 53.06 |
| Support Level | $50.36 | $1.41 |
| Resistance Level | $61.53 | $1.77 |
| Average True Range (ATR) | 1.55 | 0.15 |
| MACD | 0.65 | 0.05 |
| Stochastic Oscillator | 90.91 | 71.43 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.